7 results
The aim of this study is to evaluate the efficacy of three doses of S 066913 (5 mg, 25 mg and 100 mg o.d.) versus placebo administered for 4 weeks on atrial fibrillation and/or atrial tachycardia burden (AF/AT burden) in patients with paroxysmal…
Primary: To characterize the pharmacokinetics of imatinib in pediatric patients age 1 to less than 4 years via appropriate integrated PBPK and pop PK approaches
Primary ObjectiveTo assess the capability of the dPCR technique to predict the absence of disease relapses after imatinib discontinuation in CML patients with negative Q-RT-PCR results for longer than 18 months.Secondary Objectives• To estimate…
The primary objective of this study is to evaluate whether surgery of residual disease in patients iwth advanced GIST responding to Imatinib improves the progression free survival.The secondary objective is to correlate the pharmacokinetics of…
To investigate the efficacy (and the toxicity) of Glivec in systemic sclerosis by examining clinical outcomes (clinical and laboratory findings).
The aim of this study is to determine whether MI-E leads to a lower number of RTIs as compared to AS combined with MAC in DMD patients with a PECF< 270 l/min over a period of two years.
Primary: To compare the proportion of patients demonstrating Major Molecular Response (MMR) at 12 months (48 weeks) in the bosutinib arm with that of the imatinib arm in newly diagnosed Philadelphia chromosome positive (Ph+) chronic phase (CP)…